The WHO 2004 classification did take account for different risks of progression; therefore, ETs were subdivided into ET of benign behaviour, ET of uncertain behaviour (increased Ki-67 and/or size and/or invasion) and well-differentiated endocrine carcinomas (presence of metastases). This evidence concerns the gene MKI67 and essential thrombocythemia.